Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    P76 - Targeted Therapy - Clinically Focused - EGFR

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P76.06 - A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma

      00:00 - 00:00  |  Presenting Author(s): Dong Shen

      • Abstract

      Loading...

    • +

      P76.21 - EGFR-KDD with Duplication of Exons 18-26 Responding to Afatinib Treatment in a Patient with Lung Adenocarcinoma

      00:00 - 00:00  |  Presenting Author(s): Yiying Qian

      • Abstract

      Loading...

    • +

      P76.38 - Afatinib as a Potential Therapeutic Option for Non-small Cell Lung Cancer Patients with EGFR G724S

      00:00 - 00:00  |  Presenting Author(s): Hongyun Zhao

      • Abstract

      Loading...

    • +

      P76.55 - Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC

      00:00 - 00:00  |  Presenting Author(s): Satoshi Igawa

      • Abstract

      Loading...

    • +

      P76.70 - Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma

      00:00 - 00:00  |  Presenting Author(s): Jacqueline V. Aredo

      • Abstract

      Loading...

    • +

      P76.83 - Brain Metastasis from Lung Cancers - Intermittent High Dose Afatinib as a Palliative Salvage Therapy for EGFR+ NSCLC.

      00:00 - 00:00  |  Presenting Author(s): Jo Monsen

      • Abstract

      Loading...

    • +

      P76.85 - Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors

      00:00 - 00:00  |  Presenting Author(s): Sukhmani K. Padda

      • Abstract

      Loading...

    • +

      P76.96 - START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm+ Advanced NSCLC

      00:00 - 00:00  |  Presenting Author(s): Jianying Zhou

      • Abstract

      Loading...

    • +

      P76.99 - Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations

      00:00 - 00:00  |  Presenting Author(s): Dongqing Lv

      • Abstract

      Loading...